Table 8.

Hypoglycaemia study summary

Exposure/study number	Study summary
SGLT2i class
8.1	A large 2017 Scandinavian CVD-REAL sub-analysis explored the association of SGLT2i class vs. other OAD [54]. This study showed that compared to OADs, SGLT2i exposure use was associated with a lower risk of hospitalised severe hypoglycaemia (Table S20.1, Fig. 8). The CIs were narrow
Dapagliflozin
8.2	A medium-sized 2018 Scandinavian CVD-REAL sub-analysis explored the association of dapagliflozin vs. DPP4i exposure for hospitalised severe hypoglycaemia (as sub-analysis) [64]. There was a neutral association with hypoglycaemia (Table S20.2, Fig. 8). The CIs were narrow
8.3	A medium-sized 2019 Scandinavian study examined the association between dapagliflozin vs. OADs for hospitalised severe hypoglycaemia (as sub-analysis) [60]. There was a neutral association for hypoglycaemia (Table S20.3, Fig. 8), with narrow CIs
8.4	A medium-sized 2017 Swedish study explored the association of dapagliflozin vs. insulin on hospitalised severe hypoglycaemia (sub-analysis) [61]. There was a neutral association in both the PSM (Table S20.4, Fig. 8) and the multivariate-adjusted model (DNS). The CIs were wide

ACM all-cause mortality, CI confidence interval, CVD-REAL Comparative-Effectiveness of Cardiovascular Outcomes in New Users of Sodium–Glucose Cotransporter-2 Inhibitors, DNS data not shown, DPP4i dipeptidyl peptidase 4 inhibitor, OAD oral anti-hyperglycaemic drug, PSM propensity score-matched, SGLT2i sodium–glucose co-transporter 2 inhibitor